Hood J, Yesudasan S, Averett R
Clin Appl Thromb Hemost. 2018; 24(9_suppl):104S-116S.
PMID: 30114949
PMC: 6714860.
DOI: 10.1177/1076029618792304.
Madson Jr E, Chester E
Doc Ophthalmol. 2016; 37(2):217-43.
PMID: 27169910
DOI: 10.1007/BF00147260.
Fan N, Keegan P, Platt M, Averett R
J Vis Exp. 2015; (98):e52019.
PMID: 25867016
PMC: 4401406.
DOI: 10.3791/52019.
Peter J, Alenina N, Bader M, Walther D
Mol Cell Biochem. 2006; 295(1-2):205-15.
PMID: 16924415
DOI: 10.1007/s11010-006-9290-8.
Calvert G, Blight L, Franklin J, Oliver J, Wise P, Gallus A
Eur J Clin Pharmacol. 1980; 17(5):355-62.
PMID: 6998709
DOI: 10.1007/BF00558448.
Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue.
Porta M
Diabetologia. 1982; 23(5):452-5.
PMID: 6816652
DOI: 10.1007/BF00260961.
An epidemiological perspective of sudden death. 26-year follow-up in the Framingham Study.
Kannel W, McGee D, Schatzkin A
Drugs. 1984; 28 Suppl 1:1-16.
PMID: 6499693
DOI: 10.2165/00003495-198400281-00002.
A study of platelet-relevant parameters in patients with diabetic microangiopathy.
Porta M, Peters A, Cousins S, Cagliero E, Fitzpatrick M, Kohner E
Diabetologia. 1983; 25(1):21-5.
PMID: 6224713
DOI: 10.1007/BF00251891.
Platelet and coagulation factors in proliferative diabetic retinopathy.
Borsey D, Prowse C, Gray R, Dawes J, JAMES K, Elton R
J Clin Pathol. 1984; 37(6):659-64.
PMID: 6202721
PMC: 498841.
DOI: 10.1136/jcp.37.6.659.
Platelet adhesiveness and aggregation in relation to diabetic retinopathy.
Heath H, Brigden W, Canever J, Pollock J, Hunter P, Kelsey J
Diabetologia. 1971; 7(5):308-15.
PMID: 5134253
DOI: 10.1007/BF01219463.
Pharmacological fibrinolysis in diabetes mellitus.
Chakrabarti R, FEARNLEY G
Diabetologia. 1974; 10(1):19-22.
PMID: 4835611
DOI: 10.1007/BF00421409.
Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients.
Bizzi B, Leone G, Boni P
Acta Diabetol Lat. 1974; 11(6):437-45.
PMID: 4469856
DOI: 10.1007/BF02624583.
Successful treatment of disseminated intravascular coagulopathy complicating diabetic coma.
Nicholson G, Tomkin G
Br Med J. 1974; 4(5942):450.
PMID: 4425919
PMC: 1612557.
DOI: 10.1136/bmj.4.5942.450.
Misunderstanding or error? The UGDP report after four years.
Marigo S, ADEZATI L, Burnetti P, Pozza G, ROBBA L, URBINATI G
Acta Diabetol Lat. 1974; 11(5):357-422.
PMID: 4156992
DOI: 10.1007/BF02624579.
Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.
Huupponen R
Med Toxicol. 1987; 2(3):190-209.
PMID: 3298923
DOI: 10.1007/BF03259864.
Platelet hyperaggregation and increased plasma level of Von Willebrand factor in diabetics with retinopathy.
Bensoussan D, Levy Toledano S, Passa P, Caen J, Caniver J
Diabetologia. 1975; 11(4):307-12.
PMID: 1081963
DOI: 10.1007/BF00422396.
Current concepts of pathogenesis of diabetic retinopathy: a dysproteinemia.
LITTLE H, Sacks A, Vassiliadis A, Greer R
Trans Am Ophthalmol Soc. 1977; 75:397-426.
PMID: 613527
PMC: 1311558.
Coagulation abnormalities in diabetic coma before and 24 hours after treatment.
McLaren E, Cullen D, Brown M
Diabetologia. 1979; 17(6):345-9.
PMID: 535672
DOI: 10.1007/BF01236267.
Haemostatic variables associated with diabetes and its complications.
Fuller J, Keen H, Jarrett R, Omer T, Meade T, Chakrabarti R
Br Med J. 1979; 2(6196):964-6.
PMID: 509177
PMC: 1596588.
DOI: 10.1136/bmj.2.6196.964.
Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.
Jones R, Peterson C
J Clin Invest. 1979; 63(3):485-93.
PMID: 429567
PMC: 371977.
DOI: 10.1172/JCI109326.